What Akrinor Treats: Main Uses and Benefits

Akrinor is a medication primarily used to provide acute, supportive relief for circulatory status by addressing episodes of abnormally low blood pressure. The medication is commonly employed for the management of arterial hypotension during anesthesia and in emergency medicine. The goal is to support the management of hemodynamic instability and assists with easing the challenging symptoms that may arise from inadequate blood flow.

It is generally applied in clinical settings where a supportive physiological response is considered relevant as part of the symptomatic management of acute hypotensive states. Key indications relevant for this short-term assistance include managing sudden, significant blood pressure drops during surgical procedures, regional anesthesia, and specific scenarios involving obstetric patients, such as during Cesarean section.

Quick Fact: Relief for Acute Dizziness and Nausea

Akrinor may assist with managing the symptom cluster associated with inadequate blood perfusion, which often includes acute dizziness, nausea, and vomiting.

---

This support contributes to patients coping more steadily with the challenging symptoms that arise from acute circulatory failure. This application is relevant for short-term assistance to stabilize circulatory status and may assist with maintaining appropriate circulatory support for both the patient and the fetus.

The official regulatory documentation for Akrinor (Cafedrine/Theodrenaline) strictly defines patient eligibility, primarily driven by its classification as a Sympathomimetic Agent. Use is generally established for adult patients experiencing acute hypotension.

Contraindicated Populations

Akrinor is contraindicated in patients with specific cardiovascular and metabolic diseases where adrenergic stimulation could be dangerous, including:

• Phaeochromocytoma and Thyrotoxicosis.
• Severe Arterial Hypertension, Narrow-Angle Glaucoma, Mitral Stenosis, and pre-existing vascular conditions such as Arteriosclerosis or Aneurysm.
• Patients with Hypersensitivity to any component or those concurrently receiving Monoamine Oxidase (MAO) Inhibitors or other Indirect Sympathomimetic Drugs.

Age and Conditional Use Rules

• Pediatric Patients: Use in children and adolescents (under 18 years) is officially categorized as not established or not recommended due to insufficient data.
• Pregnancy: The medicine is documented as acceptable for use in low-risk obstetric procedures (e.g., Cesarean section), but it is contraindicated in high-risk pregnancy scenarios and should not be used prophylactically.
• Conditional Use: Caution is required, and the effect may be limited in patients with Heart Failure (NYHA 1) or those on Beta-Blocker Therapy.

Interactions with other medicines and products

Official regulatory documentation outlines specific interaction constraints for Akrinor (Cafedrine/Theodrenaline), primarily due to its sympathomimetic activity and pharmaceutical properties.

---

Contraindicated Combinations and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated because the combination carries a risk of a severe, crisis-like increase in blood pressure. This restriction is mandatory for the entire duration of MAOI treatment and for a period of two weeks following the discontinuation of the MAOI.

---

Pharmacodynamic and Chemical Interactions

Interacting Agents	Official Regulatory Description
Inhalational Anesthetics (e.g., Halothane)	Co-administration may lead to the occurrence of cardiac arrhythmias.
Beta-Blockers (e.g., Atenolol)	Simultaneous use may result in a reduction in heart rate.
Blood Pressure-Modifying Agents	Effects may be enhanced by other pressor agents or attenuated by certain blood pressure-lowering medicines.
Ceftriaxone-containing medicines	Must not be mixed with Akrinor due to pharmaceutical incompatibility.
Thiamin (Vitamin B1)	The excipient Sodium Metabisulphite is assumed to cause the breakdown of co-administered Thiamin.

---

Summary of Regulatory Constraints

The interaction profile requires adherence to a two-week timing rule for MAOIs and procedural restrictions against mixing with Ceftriaxone products. The documented interactions are based on pharmacodynamic effects (e.g., blood pressure, heart rate) and physical compatibility constraints.

Coordinated Sympathomimetic and Enzyme Modulation

The mechanism involves the direct and indirect activation of beta1-Adrenoceptors (beta1-AR) in the heart muscle and the release of endogenous norepinephrine by its Cafedrine component. This stimulation initiates the sympathetic cascade, primarily enhancing myocardial contractility, which leads to an increase in the heart's Stroke Volume and subsequent Cardiac Output.

The mechanism of action is potentiated by the inhibition of Phosphodiesterases (PDEs), primarily the PDE3 enzyme, by the theophylline component. By slowing the breakdown of cyclic AMP (cAMP), this action reinforces the beta1-AR signal, sustaining and amplifying the positive inotropic effect, which contributes to the effect on cardiac performance.

The combination is characterized by a balanced hemodynamic profile resulting from simultaneously targeting both the heart and peripheral vasculature. While the sympathetic action increases Cardiac Output (CO), the controlled alpha1-Adrenoceptor activation induces necessary vasoconstriction without causing excessive resistance. This coordinated action results in the effect being driven by enhanced cardiac performance rather than unopposed peripheral squeeze.

Akrinor is administered via a controlled intravenous (IV) bolus injection, a route utilized for immediate support to the circulatory system. The medication is supplied as a solution for injection, with each 2 mL ampoule containing the fixed-ratio combination of 200 mg Cafedrine and 10 mg Theodrenaline. Its usage is strictly confined to a supervised clinical environment, such as in anesthesia or emergency medicine, due to the acute nature of the conditions it addresses.

---

Dosing and Administration Protocol

Key Use Principle	Description
Administration Route	Intravenous (IV) bolus injection only.
Dosing Pattern	Titrated to effect in an as-needed manner; not a scheduled regimen.
Maximum Single Dose	One ampoule ( 200 mg Cafedrine / 10 mg Theodrenaline).

---

Dosing is typically individualized and responsive; the drug is administered to achieve a desired blood pressure goal, rather than following a fixed schedule. Before administration, the 2 mL solution is commonly diluted using saline (0.9% NaCl) to a 10 mL total volume. This preparation step allows healthcare providers to inject the solution incrementally for precise control over the patient's blood pressure response. Akrinor is only intended for short-term use to stabilize acute hypotensive states; it is not indicated for long-term or chronic blood pressure management.

Akrinor: Recent Clinical Evidence

This overview summarizes the formal research, including clinical trials and observational studies, that have explored the use of Akrinor. The goal is to describe what the evidence covers and where scientific uncertainty remains, without offering any clinical advice or making claims about individual outcomes.

---

Evidence for use in Arterial Hypotension during Anesthesia

Research for this specific use has been studied for many years, primarily through Randomized Controlled Trials (RCTs) and Comparative Studies. These trials were evaluated in adult patients undergoing surgical procedures, particularly those receiving regional anesthesia such as spinal blocks, where drops in blood pressure are commonly observed.

Studies explored the outcomes related to systemic or functional imbalance, specifically focusing on measured changes in Mean Arterial Pressure (MAP). Researchers monitored the immediate hemodynamic responses and the time associated with blood pressure change compared to other agents. The findings describe patterns observed in the short-term measurement of blood pressure, and research highlights changes measured during the surgical phase.

Evidence for use in Hypotension during Cesarean Section

The evidence for managing low blood pressure during Cesarean sections comes from dedicated RCTs and Comparative Studies in the obstetric population. These trials were evaluated in pregnant women receiving regional anesthesia for delivery. Research explored the acute period by measuring both maternal hemodynamic status and monitoring for effects on the neonate. The studies examined outcomes such as the short-term measurement of the mother's blood pressure and heart rate, as well as fetal outcomes like Apgar scores.

---

Research Gaps and What is Still Uncertain about Akrinor

While research helps show what has been observed so far, the evidence landscape highlights specific gaps and areas of uncertainty:

• Comparative evidence is lacking against an inactive control substance for the acute reversal of low blood pressure, as most trials compare Akrinor to other active treatments.
• Long-term effects are not fully established, and there is limited information for long-term outcomes due to the acute nature of the studied uses.
• Findings describe group patterns, not personal outcomes, and study results reflect the specific, often acute, conditions under which they were conducted.

Common questions about Akrinor (FAQ)

---

Q: What are the active ingredients in Akrinor?

Akrinor is a combination medicine with two primary active ingredients: Cafedrine Hydrochloride and Theodrenaline Hydrochloride. These two components are supplied together in a fixed ratio in the solution for injection.

Q: How does Akrinor specifically increase a patient's blood pressure?

According to official product information, Akrinor works by stimulating the heart to increase its force of contraction, which boosts the amount of blood the heart pumps (cardiac output). Additionally, it causes a necessary tightening of blood vessels (vasoconstriction). This combination of enhanced cardiac performance and controlled vasoconstriction supports the overall rapid increase in blood pressure.

Q: Can Akrinor be administered via a subcutaneous (SC) or intramuscular (IM) injection?

Official regulatory documents indicate that this medicine is administered exclusively via controlled intravenous (IV) bolus injection. Routes such as subcutaneous (under the skin) or intramuscular (into the muscle) injection are not included in the official administration instructions for this product.

Q: Is Akrinor suitable for children?

The official product information indicates that the use of Akrinor in children and adolescents, defined as those under 18 years of age, is currently not recommended. This restriction is in place because there is insufficient clinical data to establish its use and safety for patients in this age group.

Q: Does Akrinor require dilution before use?

Official prescribing information indicates that the 2, mL ampoule solution is often diluted by healthcare providers before administration with saline to a total volume of 10, mL. This preparation step allows the healthcare provider to inject the medicine incrementally for precise control over the patient’s blood pressure response.

Q: Is it safe to drive or operate machinery after receiving Akrinor?

Since Akrinor is administered in a supervised clinical setting, such as a hospital or surgical environment, and can cause temporary side effects like headache, anxiety, or tremor, official safety warnings generally note that driving or operating complex machinery is restricted immediately following its use.

Q: What should I do if a dose is missed (e.g., in a planned regimen)?

This medicine is for immediate, short-term use and is administered by a healthcare professional only when needed for an acute drop in blood pressure. It is not prescribed for a scheduled home regimen. Because of this, the concept of a 'missed dose' does not apply to this medicine.

The storage and disposal instructions for Akrinor (Cafedrine/Theodrenaline solution for injection) are defined by official regulatory labeling to ensure product stability and sterility.

Storage Requirements

Akrinor must be stored at a temperature not exceeding 30 °C (86 °F) and must not be frozen. To protect the solution from light, it is mandatory to store the ampoule or syringe in the original outer carton.

As a sterile injectable solution, the product must be used immediately after the sterile packaging is opened. Any remaining solution after administration, as the product is for single use only, must be discarded.

Child Safety and Disposal

As with all medicines, Akrinor must be kept out of the sight and reach of children.

Disposal of unused or expired medicine must comply with local requirements. The medicine should not be disposed of via wastewater or household trash; consult a pharmacist for guidance on local collection programs.